Today's Pharma Pulse
Parabilis Medicines raises $770.5M in record biotech IPO
Parabilis Medicines completed the largest biotech IPO to date, pricing 33.5 million shares at $20 each and generating $770.5 million in gross proceeds. The stock jumped 58% on its first full trading day before settling at $27.26 a week later.
Kyverna Posts Positive Phase 1 Data for Miv-Cel CAR‑T in Rheumatoid Arthritis
Kyverna Therapeutics announced that its autologous CD19‑targeting CAR‑T candidate miv-cel achieved positive early‑stage outcomes in ACPA‑positive, treatment‑refractory rheumatoid arthritis patients. The data, presented at the EULAR 2026 congress, could mark a new therapeutic avenue for autoimmune disease beyond oncology.
Alnylam Inks $2 B AI Partnership with Inceptive Nucleics to Speed RNAi Drug Discovery
Alnylam Pharmaceuticals announced a partnership with AI‑driven biotech Inceptive Nucleics valued at up to $2 billion, featuring a $30 million upfront payment. The deal merges Alnylam’s RNA interference platform with Inceptive’s generative AI models to fast‑track nucleic‑acid drug design under Alnylam’s 2030...
Certain Postapproval Requirements and Resources for ANDAs
The FDA released a final Level 2 guidance (Docket FDA‑2017‑D‑6821) to clarify post‑approval requirements for holders of abbreviated new drug applications (ANDAs) under section 505(j) of the FD&C Act. The document outlines statutory and regulatory obligations, points to related guidances, and provides...
Lacripep for Neurotrophic Keratitis Gets FDA Designations
TearSolutions' synthetic peptide Lacripep received FDA orphan‑drug and fast‑track designations, clearing a regulatory path for the first‑in‑class therapy for neurotrophic keratitis. The company has dosed the initial cohort in a phase 2 multicenter, randomized trial enrolling about 54 patients who will...
Blood Test Predicts Lung Cancer Risk Years Early
A very impressive study for how we could prevent lung cancer more than 5 years before it is diagnosed. Using machine learning, discovery of a 14-plasma protein signature of risk that predicts responsiveness to an antibody therapy to interleukin, IL-1β Validated...
On a Mission to Standardize Proteomics Workflows
Evosep, a Danish biotech, announced the launch of Evosep Proteomics, an end‑to‑end ecosystem that standardizes sample preparation through Evokit kits and the Lupo system and integrates with its LC‑MS platforms. The solution promises reproducible, low‑variance proteomic data at a target...
What’s Next in Obesity and MASH Clinical Research with MetaVia’s Hyung Heon Kim — Episode 258
In episode 258 of the Xtalks Life Science Podcast, MetaVia CEO Hyung Heon Kim outlines the evolving cardiometabolic landscape, linking obesity, diabetes, MASH (metabolic‑associated steatohepatitis) and cardiovascular risk. He highlights shifting priorities in obesity treatment—muscle preservation, metabolic health and durable outcomes—and explains...
Why ASCO Stood Up for Daraxonrasib: RASolute 302, Pancreatic Cancer Survival, and the New KRAS Investment Thesis
At ASCO 2026, Revolution Medicines presented RASolute 302, a Phase 3 trial of daraxonrasib in second‑line metastatic pancreatic ductal adenocarcinoma. The study enrolled 500 patients and showed median overall survival of 13.2 months versus 6.7 months with chemotherapy, a hazard ratio...
An ADC Specialist Sinks on Safety Concerns for Blood Cancer Drug
ADC Therapeutics reported that its antibody‑drug conjugate Zynlonta met the primary endpoint in a Phase 3 trial, extending progression‑free survival by 1.4 months when combined with rituximab. However, the study recorded 27 deaths in the Zynlonta arm versus nine in the...
Alpha Tau, Tolmar Ink $20M Deal to Co‑Develop Alpha DaRT Prostate Cancer Therapy
Alpha Tau Medical (DRTS) and Tolmar International announced a strategic collaboration to develop and commercialize Alpha DaRT for prostate cancer in the United States. Tolmar will invest $20 million in equity, fund a $15 million U.S. production facility and secure exclusive U.S....
MAIA Gets FDA Clearance to Expand Phase 2 THIO‑101 Lung Cancer Trial
MAIA Biotechnology announced that the U.S. FDA cleared an amendment to its IND, allowing U.S. enrollment for an expanded Phase 2 THIO‑101 trial of ateganosine in non‑small cell lung cancer. The clearance follows fast‑track designation and new manufacturing efficiencies, positioning the...
Pharma Is Betting Big on PD-1/VEGF Bispecifics. But Are Companies Chasing the Wrong Target?
Pharma has poured billions into PD‑1/VEGF bispecific antibodies after ivonescimab outperformed Keytruda in a 2024 lung‑cancer trial. A China‑based phase 3 study showed the drug cut death risk by 34% versus chemotherapy plus a PD‑1 inhibitor, reigniting investor enthusiasm. However, analysts...
Meet Dalton, a New AI-Powered Drug Discovery Platform
DaltonTx, a UK start‑up spun out of AstraZeneca, Exscientia and Oxford, has launched its end‑to‑end AI drug‑discovery platform called Dalton. The system handles data ingestion, model training, molecular design, synthesis and decision‑making, creating a continuous learning engine for both small‑molecule...
Xbrane Reports the US FDA Acceptance of Resubmitted BLA for Lucamzi (Biosimilar, Lucentis)
Xbrane Biopharma announced that the U.S. FDA has accepted its resubmitted biologics license application for Lucamzi, a biosimilar to Lucentis, and set a BsUFA action date of October 29, 2026. The resubmission, filed in April 2026, addressed the complete response...
/https://tf-cmsv2-smithsonianmag-media.s3.amazonaws.com/filer_public/a9/a2/a9a2af7e-39e3-43f1-82d8-829ba51d2f8c/jonas_salk_3.jpg)
When the Fear of Polio Gripped the World, Jonas Salk’s Determination Led to a Liberating Medical Breakthrough
In the early 1950s, Jonas Salk pioneered an inactivated‑virus polio vaccine that defied prevailing belief that only live viruses could confer immunity. After successful animal work, his team launched a massive 1.8 million‑child field trial in 1954, employing double‑blind and observational...
EULAR 26 Hears of Treatment Advances in Lupus
Phase‑2 and phase‑3 trials presented at EULAR showed promising results for three first‑in‑class lupus drugs. Johnson & Johnson’s FcRn inhibitor nipocalimab achieved a 53.5% SRI‑4 response at 24 weeks versus 46.7% with placebo, with benefits sustained to 52 weeks. Biogen/UCB’s...
Innovent Reports the P-III Trial Results on Arcotatug Tavatecan in G/GEJ Adenocarcinoma
Innovent announced that its CLDN18.2‑targeted antibody‑drug conjugate, arcotatug tavatecan (IBI343/TAK-921), met the primary endpoint of improved progression‑free survival in the interim analysis of the Phase III G‑HOPE‑001 trial. The study compared the ADC with investigator‑selected therapies in patients with locally advanced...
Revolutions in Drug Delivery
Recent drug approvals highlight that delivery engineering can be as transformative as new molecular targets. Lenacapavir, a capsid inhibitor for HIV, uses a subcutaneous depot to maintain protective levels for months, allowing twice‑yearly PrEP dosing. The GalNAc‑siRNA platform adds a...
Semaglutide Slows Epigenetic Aging Markers in First Human Trial of GLP‑1 Drug
Researchers at UC San Diego reported that semaglutide, the GLP‑1 drug behind Ozempic and Wegovy, slowed DNA‑based aging clocks in a 32‑week, placebo‑controlled trial of 108 adults with HIV‑related lipohypertrophy. The findings suggest a new anti‑aging avenue for a drug...
Alvotech Resubmits FDA BLAs for Simponi and Eylea Biosimilars Amid Reykjavik Facility Remediation
Alvotech announced Thursday that it has resubmitted Biologics License Applications for its Simponi (AVT05) and Eylea (AVT06) biosimilars following FDA observations at its Reykjavik manufacturing site. The company expects a six‑month review, a step that could unlock U.S. market entry...
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery, a San Francisco AI drug‑discovery startup, has secured high‑profile partnerships with Eli Lilly and Pfizer after unveiling its next‑generation antibody‑design model, Chai‑3. Valued at $1.3 billion, the company claims Chai‑3 doubles the success rate of its prior model and produces...
Alvotech Reports the US FDA’s BLA Resubmission for AVT05 (Bisomilar, Simponi and Simponi Aria) and AVT06 (Biosimilar, Eylea)
Alvotech announced that the U.S. Food and Drug Administration has received resubmitted Biologics License Applications for AVT05, a biosimilar to Simponi and Simponi Aria, and AVT06, a biosimilar to Eylea (aflibercept). The resubmissions follow Alvotech’s corrective actions addressing FDA observations...
STAT+: Does Revolution Medicines’ Pancreatic Cancer Drug Have Even Greater Potential?
Revolution Medicines’ KRAS‑G12D inhibitor daraxonrasib earned a certain approval for patients with metastatic pancreatic cancer whose disease progressed after chemotherapy. The approval hinges on the company’s speed in filing an FDA application, after which the drug is expected to be...
![[Comment] Endothelin Antagonism in IgA Nephropathy: Promise Ahead of Proof?](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/cebd8e679178b50bb91f72441f87e2b6.webp)
[Comment] Endothelin Antagonism in IgA Nephropathy: Promise Ahead of Proof?
A recent Lancet commentary evaluates endothelin‑A receptor antagonists (ERAs) as a therapeutic avenue for IgA nephropathy, citing mechanistic data that link intrarenal endothelin‑1 over‑expression to inflammation, fibrosis, and nephron loss. The authors highlight the ALIGN phase‑3 trial, where atrasentan modestly...
Novartis' Cosentyx Doubles Remission Rate in Polymyalgia Rheumatica Trial
Novartis announced that its IL‑17 inhibitor Cosentyx achieved twice the sustained remission rate of placebo in the Phase III REPLENISH trial for polymyalgia rheumatica (PMR). The data, published in the New England Journal of Medicine and presented at the 2026 EULAR...
FDA Expands Tremfya’s Label in Psoriatic Arthritis
The FDA has broadened the label for Janssen’s Tremfya (guselkumab) to cover inhibition of structural joint‑damage progression in adults with active psoriatic arthritis. The decision follows the APEX phase‑III trial, which demonstrated significantly lower radiographic progression at 24 weeks versus...
Rethinking Hair Loss Treatment
In a June 4, 2026 episode of BioSpace’s podcast Denatured, Pelage Pharmaceuticals CEO Daniel Gil and Eli Lilly immunology SVP Francisco Ramírez‑Valle discuss a regenerative strategy to treat hair loss. They explain why the field has seen few breakthroughs and describe early proof‑of‑concept data...
Gilead’s Livdelzi Hits Positive Phase 3 Endpoint, Lifts Stock
Gilead Sciences announced that its investigational drug Livdelzi (seladelpar) met the primary endpoint in the Phase 3 IDEAL trial for primary biliary cholangitis (PBC). The data, released on June 3, sent Gilead’s shares higher and positioned the company for a...
Legend’s Ex Vivo Design Expertise Underpins in Vivo CAR T Efficacy
Legend announced its first‑in‑human in vivo CAR T trial, reporting response rates that rival traditional ex vivo cell therapies. The company leveraged design principles from its successful ex vivo platform to engineer dual‑targeted, high‑affinity T‑cells that can be dosed directly in patients. While...
Tenaya to Unveil Interim MyPEAK-1 Data for Gene Therapy in MYBPC3-Associated HCM
Tenaya Therapeutics announced it will present interim data from Cohort 1 and Cohort 2 of its MyPEAK-1 Phase 1b/2 trial of TN-201, a gene‑editing therapy for adults with MYBPC3‑associated hypertrophic cardiomyopathy. The webcast is set for June 3, 2026, at 8:00 a.m. ET, and the news...
Snowflake Secures Sanofi AI Drug‑Development Platform Deal, Expanding Pharma Cloud Footprint
Snowflake announced at its Summit 26 in San Francisco that Sanofi will use the Snowflake AI Data Cloud to power a new AI‑driven drug‑development platform, including the "Concierge for Field" sales agent. The partnership extends Snowflake’s reach across R&D, procurement,...
This Mysterious Lung Disease Affects Millions of People — but a Drug Tested in Mice Shows Promise
Idiopathic pulmonary fibrosis (IPF), a fatal scarring disease affecting millions, currently has only two drugs that merely slow progression. Researchers at the National Institute of Environmental Health Sciences discovered that mice lacking the toll‑like receptor 5 (TLR5) develop more severe...
Former FDA Officials: There’s Opportunity to Rebuild the Agency — But Not the Way It Was
Former FDA leaders argue the agency’s decades‑old center structure is obsolete and hampers efficiency. Rick Pazdur suggests replacing CDER and CBER with disease‑focused centers such as oncology, neurology, and infectious disease, and calling on academic experts to fill staffing gaps....
Breakthrough Ovarian Cancer Drug Offers Patients More Time and Better Quality of Life
The NHS has approved mirvetuximab soravtansine, an antibody‑drug conjugate that targets folate‑receptor‑alpha, for platinum‑resistant ovarian, peritoneal and fallopian‑tube cancers. Clinical data show median survival extending from 12.8 to 16.5 months with fewer side‑effects, and the treatment is administered every three...
STAT+: Alnylam to Partner with Inceptive Nucleics for AI Foundation Models for RNAi Therapeutics
Alnylam Pharmaceuticals has entered a three‑year strategic collaboration with Inceptive Nucleics, a startup founded by former Google Brain researcher Jakob Uszkoreit. The deal is valued at up to $2 billion, with $30 million paid upfront in cash and equity. Inceptive will apply...
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
Long‑term data presented at ASCO 2026 confirm that the oral CSF‑1R inhibitor pimicotinib delivers durable tumor shrinkage and functional gains in patients with tenosynovial giant cell tumor (TGCT). In the phase 3 MANEUVER trial, objective response rates hovered around 75‑80% across...
Pasteurized Akkermansia Muciniphila Supplement Cuts Weight Regain in 90‑person Trial
Researchers gave 90 overweight adults who shed at least 8% of their weight a daily pasteurized Akkermansia muciniphila supplement for 24 weeks. Participants regained far less weight than those on placebo, suggesting the gut microbe could become a tool for...
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
Acoramidis (Attruby) demonstrated sustained reductions in all‑cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months in an open‑label extension of the ATTRibute‑CM trial. The extension enrolled 389 patients, comparing continuous treatment with delayed initiation after placebo crossover. Continuous...
Eli Lilly Secures $162 M Upfront in Asian Deals and Wins Full PBM Coverage for Obesity Portfolio
Eli Lilly announced two Asian licensing agreements on June 1, 2026, delivering $162 million in upfront payments and up to $4.2 billion in milestones. The same day, CVS Caremark added Lilly’s oral obesity pill Foundayo and injectable Zepbound to its formulary, covering roughly...
The BioPharm Brief: RNA Editing, Cardiac Remodeling, Rare Disease Gene Therapy
Eli Lilly has signed a licensing deal with Ascidian Therapeutics to use its RNA exon‑editing platform for inherited kidney diseases, underscoring the rise of reversible RNA‑based medicines. Tenaya Therapeutics presented interim results for its TN‑201 gene‑therapy, showing cardiac remodeling and lowered...
Small Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+
Incyte has expanded its AI‑driven drug discovery partnership with Genesis Molecular AI to at least five targets, raising Genesis's potential upside to over $1 billion. The deal adds a $120 million upfront payment—$80 million cash and $40 million in equity—and up to $232 million per...
New Antibiotic, Manikomycin, Acts on Novel Ribosomal Target
Researchers at McMaster University have isolated a new antibiotic, manikomycin, from Streptomyces rimosus. The compound uniquely binds the E‑site of the bacterial ribosome’s large subunit, a target never exploited by existing drugs, and shows activity against multidrug‑resistant Enterobacteriaceae. The discovery...
We Must Keep Pace as Alzheimer’s Treatment Enters a New Phase
Alzheimer’s research has entered a new era as the first disease‑modifying drugs demonstrate functional benefits for patients. The Alzheimer’s Association reports more than 150 therapies in roughly 200 trials, targeting at least 17 biological pathways beyond amyloid and tau. Real‑world...
Sacituzumab Govitecan Combo Benefits Breast Cancer Subset
The phase 3 ASCENT‑04 trial showed that first‑line sacituzumab govitecan plus pembrolizumab improves progression‑free survival 2 (PFS2) by 33% versus chemotherapy plus pembrolizumab in PD‑L1‑positive metastatic triple‑negative breast cancer. The study enrolled 443 patients, permitted crossover to sacituzumab govitecan monotherapy, and reported...
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
Cellares and TScan Therapeutics have signed an agreement to evaluate fully automated manufacturing of TSC-101, TScan’s lead TCR‑T therapy for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The collaboration will use Cellares’ Cell Shuttle® end‑to‑end platform and Cell Q™...
Stanford Study Finds Existing Drug Reverses Muscle Loss From GLP‑1 Weight‑Loss Therapies
Stanford Medicine scientists demonstrated that a prostaglandin‑dehydrogenase inhibitor (PGDHi), already in trials for age‑related sarcopenia, prevents muscle loss and restores strength in mice treated with semaglutide, the GLP‑1 drug behind Ozempic and Wegovy. The pre‑clinical data could pave the way...
Legend Biotech Shares Surge 42% on Positive Phase 1 Data for LB2501 Lymphoma Therapy
Legend Biotech Corp. announced encouraging preliminary Phase 1 results for its LB2501 therapy in B‑cell non‑Hodgkin lymphoma, driving a 42% jump in its stock. The investigational CAR‑T candidate showed activity in 12 patients across two dose levels, highlighting a potential...
Rallybio to Acquire Avenzo in $215 Million Private‑Placement‑Backed Merger
Rallybio Corp. announced a definitive agreement to acquire Avenzo Therapeutics, creating a combined entity that will trade as Avenzo Therapeutics (AVZO). The deal is paired with an oversubscribed $215 million private placement, funding operations into late 2028 and leaving pre‑Rallybio shareholders...
New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge
On June 3, 2026 the FDA’s Center for Biologics Evaluation and Research issued a draft guidance allowing sponsors of somatic genome‑editing gene therapies to leverage existing CMC, nonclinical and clinical data in regulatory submissions. Sponsors must provide a product‑specific scientific rationale and...
Legend Biotech's LB2501 Shows Promise in Phase 1 Lymphoma Trial, Shares Surge 42%
Legend Biotech announced encouraging preliminary results from its LB2501 CD19/CD20 dual‑targeting CAR‑T trial in B‑cell non‑Hodgkin lymphoma, lifting the stock more than 42%. The data, from 12 patients across two dose levels, suggest a manufacturing‑free, single‑infusion therapy that could reshape...